Assay for measurement of antibodies binding to a therapeutic monoclonal antibody
Methods and system for determination of an anti-<therapeutic monoclonal antibody> antibody (anti-<TmAB>AB) in vitro in a sample from a patient treated with a therapeutic monoclonal antibody (TmAB). Also, methods and systems for the determination of antigen specific antibodies of a particular immunoglobulin class and for the identification of a patient who is at risk of developing an adverse drug reaction (ADR) during treatment with a TmAB.
1. A method for determination of an anti-<therapeutic monoclonal antibody> antibody (anti<TmAB>AB) in a whole blood, serum and plasma sample from a patient treated with a therapeutic monoclonal antibody (TmAB), the method comprising:
a) providing a F(ab) fragment of the TmAB bound to a solid phase;
b) incubating the solid phase provided in (a) with the sample, thereby binding the anti <TmAB>AB to the solid phase via the F(ab) fragment;
c) incubating the solid phase obtained in (b) with a monoclonal antibody <h-Agg.-IgG>, whereby said monoclonal antibody binds to the anti<TmAB>AB, wherein said monoclonal antibody is an IgM antibody having a dissociation constant (=K D ) value of about 10 −6 mol/l-10 −8 mol/l; and
d) detecting the monoclonal antibody<h-Agg.-IgG> bound in (c) and thereby determining the anti<TmAB>AB in the sample.
2. The method according to claim 1 , wherein the TmAB is selected from the group consisting of chimeric antibodies (CA) and humanized antibodies (HA).
3. The method according to claim 1 , wherein the TmAB is selected from the group consisting of infliximab, adalimumab, certolizumab and rituximab.
4. The method according to claim 1 , wherein the F(ab) fragment is bound to the solid phase by a binding system selected from the group consisting of biotin/steptavidin, biotin/avidin, and biotin/anti-<biotin> antibody.
5. The method according to claim 1 , wherein the monoclonal antibody is an antibody having a dissociation constant (K D ) value of between approximately 10 −7 mol/l-10 −8 mol/1.
6. The method according to claim 1 , wherein the monoclonal antibody<h-Agg.-IgG> is labeled.
7. The method according to claim 6 , wherein the monoclonal antibody<h-Agg.-IgG> is labeled with Dig.
8. The method according to claim 7 , wherein the Dig-labeled monoclonal antibody <h-Agg.-IgG> is detected by incubating with an anti-<Dig> antibody conjugated to a detectable label.
9. The method according to claim 8 , wherein the detectable label is selected from the group consisting of luminescent labels, chemiluminescent labels, electrochemiluminescent labels, fluorescent labels, and radioactive labels.